Daiichi Sankyo Taps ATLATL to Accelerate Drug R&D in Asia-Pacific

SHANGHAI – April 08, 2026 – Japanese pharmaceutical giant Daiichi Sankyo has entered into a strategic agreement with ATLATL Innovation Center, a move set to deepen its integration into the burgeoning Asia-Pacific (APAC) biotech ecosystem. The partnership, announced yesterday, will leverage ATLATL's extensive regional network and unique R&D platform to identify novel technologies and accelerate the development of new medicines for patients globally.

The collaboration tasks ATLATL, a self-described builder of life science innovation ecosystems, with scouting high-quality R&D platform technologies for Daiichi Sankyo. This alliance aims to streamline the complex journey from scientific discovery to clinical implementation, harnessing the dynamism of one of the world's fastest-growing innovation hotspots.

A Strategic Bet on APAC's Biotech Boom

This partnership is more than a standard collaboration; it's a significant indicator of a broader strategic shift in global pharmaceuticals. The APAC region has rapidly transformed from a market of followers into a global hub for biopharmaceutical innovation. In just five years, the region's contribution to the global innovative drug pipeline has surged from 28% to an impressive 43%, outpacing both the United States and Europe in pipeline growth. China, in particular, now accounts for nearly 29% of the global innovative pipeline.

Daiichi Sankyo, with its 2025 vision of becoming a "Global Pharma Innovator with Competitive Advantage in Oncology," is placing a calculated bet on this regional momentum. The company already has a substantial footprint in the area, including its Shanghai Daiichi Sankyo Pharmaceutical subsidiary established in 1999. This new agreement signals a desire to move beyond a traditional sales and manufacturing presence and embed its R&D engine directly into the local innovation fabric.

This strategy is further underscored by Daiichi Sankyo's recent announcement of a $1.9 billion investment in new manufacturing facilities, with a significant portion dedicated to its cancer drug portfolio in locations including China. By partnering with ATLATL, the company gains a crucial bridge to the region's most promising startups, academic institutions, and growth-stage companies scattered across key hubs like Shanghai, Beijing, Shenzhen, Hong Kong, and Singapore.

The 'Super Server': A New Model for Pharma Innovation

At the heart of this deal is ATLATL's innovative "Super Server" model, a concept designed to redefine how biotech R&D is conducted. The model functions as a one-stop global innovation platform, integrating state-of-the-art R&D infrastructure, on-site technical services, and investment support. This approach effectively unbundles the research process, allowing scientists to focus on experimental design and strategic direction while expert technicians handle the intricate bench work.

ATLATL’s platform transforms the traditionally capital-intensive nature of biotech R&D into a more agile, capital-light operating model. It offers everything from private minilabs supported by a large core facility to "Cloud Biolabs," which enable researchers to design and execute experiments remotely. This dramatically lowers the barrier to entry for early-stage companies and accelerates development timelines.

The efficacy of this model is not just theoretical. Since its inception, ATLATL has supported over 100 early-stage biotechs and projects, helping them raise over 10 billion yuan in funding, secure 80 patents, and advance 21 drug candidates into clinical trials. Prominent biotech firms such as Mabwell, GRIT Biotechnology, and LaNova Medicines have emerged from its ecosystem. This proven track record of nurturing innovation from the ground up is precisely what makes ATLATL an attractive partner for a pharmaceutical powerhouse like Daiichi Sankyo, which is seeking to tap into external innovation to fuel its pipeline.

Accelerating the Path from Bench to Bedside

The ultimate goal of this alliance is to deliver new therapies to patients faster. The synergies between the two organizations are particularly potent in oncology, Daiichi Sankyo's primary R&D focus. The company has built a world-class reputation on its proprietary DXd Antibody-Drug Conjugate (ADC) technology, which is the foundation for blockbuster drugs like Enhertu and a pipeline of over a dozen other cancer-fighting candidates.

ATLATL's capabilities are a direct match for these ambitions. Its R&D centers are equipped with specialized platforms for large molecule drug research, gene and cell therapy, AI-powered drug screening, and preclinical pharmacology. This expertise can help Daiichi Sankyo more rapidly identify new targets, optimize existing ADC candidates, and explore next-generation therapeutic modalities.

The collaboration could significantly impact the development of gene and cell therapies, an area of interest for both companies. By leveraging ATLATL's cutting-edge capabilities in gene editing, organoids, and multi-omics, Daiichi Sankyo can de-risk and accelerate its foray into these complex but potentially transformative fields.

While oncology is the clear focal point, the benefits could extend across Daiichi Sankyo's broader interests, which include nervous system disorders, cardiovascular diseases, and rare diseases. Access to ATLATL's diverse technology platforms could uncover novel approaches in these areas as well. By embedding itself within ATLATL's network, Daiichi Sankyo is not just outsourcing tasks; it is gaining a real-time window into the scientific breakthroughs happening across Asia, ensuring it remains at the forefront of medical innovation. This partnership represents a modern, symbiotic relationship where global scale meets regional agility, a fusion that could ultimately redefine the pace at which life-saving drugs reach the patients who need them most.